Incheon, S. Korea - Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today announced that the company was awarded the EcoVadis Platinum Sustainability Rating, the highest recognition given, for the company's sustainability management.

The Platinum Rating places Samsung Biologics in the top one percent of the over 100,000 companies assessed by EcoVadis, a global evaluation platform that assesses the corporate social responsibility performances of companies in four main areas: Environment, Labor & Human Rights, Ethics, and Sustainable Procurement. Samsung Biologics received the Gold Sustainability Rating in 2022.

'The Platinum Rating underscores our sustainability leadership and reflects our unwavering commitment to decarbonization, ethics, and responsible business practices,' said John Rim, CEO and President of Samsung Biologics. 'We understand that sustainability is increasingly important to all our customers and this latest accreditation reaffirms our mission in creating a healthier future for society through better services and business practices.'

Samsung Biologics has been publishing annual Environmental, Social, and Governance reports, outlining its green strategies towards decarbonization and efforts to engage suppliers to minimize potential social and ethical risks. The company is committed to achieving zero greenhouse gas emissions and 100% renewable energy across its sites and supply chains by 2050.

Samsung Biologics is also a member of the Sustainable Markets Initiative (SMI) and was the first CDMO to receive the SMI's Terra Carta Seal, in recognition of the company's efforts to drive innovation and demonstrate commitment to the creation of sustainable markets. Samsung Biologics has also joined global initiatives, including the Sustainable Aviation Buyers Alliance and the United Nations Global Compact.

(C) 2024 Electronic News Publishing, source ENP Newswire